{"id":"W4284989340","doi":"10.1093/jjco/hyac105","title":"A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20)","year":2022,"lang":"en","type":"article","venue":"Japanese Journal of Clinical Oncology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cytodiagnostics (Canada)","funders":"Japan Agency for Medical Research and Development","keywords":"Gemtuzumab ozogamicin; Medicine; Minimal residual disease; Internal medicine; Myeloid leukemia; Induction chemotherapy; Oncology; Acute promyelocytic leukemia; Hematopoietic stem cell transplantation; Clinical endpoint; Leukemia; Transplantation; Clinical trial; Calicheamicin; Chemotherapy; Stem cell; CD33; CD34","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002464173,0.00132948,0.001965469,0.0003912085,0.0002842151,0.000613941,0.0007308194,0.001083927,0.001964713],"category_scores_gemma":[0.001215371,0.0002926736,0.001398957,0.0003586754,0.0007882328,0.0005153816,0.0004610847,0.002494392,0.0003305187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006951338,"about_ca_system_score_gemma":0.00160391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004862512,"about_ca_topic_score_gemma":0.001494472,"domain_scores_codex":[0.9992357,0.0004948743,0.0000311039,0.00009280145,0.00005427084,0.00009122513],"domain_scores_gemma":[0.9990312,0.0001764018,0.0002471744,0.00009153576,0.00004516998,0.0004085793],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9194709,0.02606651,0.003863057,0.0003996712,0.001114275,0.00005639721,0.00006151455,0.0009910077,0.008685024,0.0003150366,0.001092411,0.03788426],"study_design_scores_gemma":[0.7935576,0.1981076,0.005012175,0.00001925098,0.0005013109,0.00004965658,0.00001313413,0.0005884682,0.001148361,0.0001437044,0.000846278,0.00001247743],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895727,0.002116088,0.0009555363,0.0004636976,0.0001716248,0.00473959,0.0007721737,0.00008450688,0.001124035],"genre_scores_gemma":[0.9799814,0.001560606,0.004401344,0.001142469,0.0002567811,0.00876198,0.002188247,0.00002889121,0.001678318],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002464173,"threshold_uncertainty_score":0.01303196,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05386085830409168,"score_gpt":0.4327060525568209,"score_spread":0.3788451942527292,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}